Images from the exhibition and seminar floors at the 18th annual event in Paris, the most well-attended meeting to date.
March 6–8, 2006 Paris, France
The DIA reported record-breaking attendance at its 18th Annual EuroMeeting held in Paris, France. The conference proved to be an international success and a neutral forum for the latest information and developments on EU Directive initiatives, pediatric regulations, the Pediatric Committee, technology research and platforms, pharmacogenomics, pharmacovigilance, and risk management.
The 14 tracks gave conference goers more than enough workshops to choose from. The Exhibitors floor was busy with information seekers, networkers, great giveaways, and delightful Parisian pastries.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
FDA Grants Ziftomenib with Breakthrough Therapy Designation for NPM1-Mutant Acute Myeloid Leukemia
April 23rd 2024Data from the Phase Ib portion of the KOMET-001 trial showed that the once-daily oral treatment may provide a substantial improvement over available therapies for relapsed/refractory NPM1-mutant acute myeloid leukemia.